Minnesota is currently home to 2105 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
Recruiting
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharma... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: The Children's Heart Clinic/Children's Minnesota, Minneapolis, Minnesota
Conditions: Heart Block Complete, Heart Block Second Degree
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Essentia Health, Duluth, Minnesota
Conditions: Type2Diabetes, ASCVD
Register for Updates
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
NCT04221815
Recruiting
Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, util... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: St. Luke's Hospital of Duluth, Duluth, Minnesota
Conditions: Atherosclerosis
Register for Updates
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Solid Tumor, Adult
Register for Updates
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
NCT06108024
Recruiting
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Minnesota Clinical Study Center, New Brighton, Minnesota
Conditions: Seborrheic Keratosis
Register for Updates
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
NCT03161431
Recruiting
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Melanoma Stage Iii, Melanoma Stage Iv
Register for Updates
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
NCT01193088
Recruiting
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Minnesota, Maple Grove, Minnesota
Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
Register for Updates
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
NCT01193075
Recruiting
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Charcot Marie Tooth Disease
Register for Updates
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
NCT04655118
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Myelofibrosis, Indolent Systemic Mastocytosis
Register for Updates
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Register for Updates
Multi-level Predictors of Structural Racism and Discrimination and Associations With Health and Well-being Across the Life Course in Diverse Families
NCT05744973
Recruiting
Minoritized populations face mutually reinforcing levels of structural disadvantage that contribute to poor health. Despite recognition that social and economic stratification, environmental conditions, and policy are critical determinants of health disparities, there has been limited effort in expanding interventions beyond the individual level to disrupt systemic causes of health. This is in part due to the challenges of describing how racism and discrimination have become systematized over ti... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
05/06/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Racially/Ethnically Diverse Families From Urban Settings
Register for Updates
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
NCT05444582
Recruiting
This is a prospective clinical research study to test the effectiveness of the Levonorgestrel (LNG) 52 mg Intrauterine Device (IUD) for emergency contraception (EC) and same-day start use that will enroll people receiving care at Planned Parenthood affiliates across the U.S. Our prior work demonstrated efficacy (shows that it works in an ideal setting) for the LNG 52 mg IUD for these uses and this study will test effectiveness (how well it works in the real world) in a larger, heterogenous popul... Read More
Gender:
FEMALE
Ages:
Between 16 years and 35 years
Trial Updated:
05/06/2024
Locations: Planned Parenthood North Central States, Saint Paul, Minnesota
Conditions: Contraception
Register for Updates